Pola‐R‐CHP for frontline therapy in DLBCL: Are we saving money by spending more?

The study by Kambhampati et al. offers the first European perspective on cost‐effectiveness of pola‐R‐CHP in the frontline line treatment of DLBCL patients. Nevertheless, the applicability of these results in other European settings remain questionable: Germany is indeed a wealthy country with wide...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2023-08, Vol.202 (4), p.731-733
Main Authors: Vitolo, U., Frascione, P. M. M., Bonello, F.
Format: Article
Language:English
Subjects:
cost‐effectiveness analysis
DLBCL
Hematology
Lymphoma
Patients
pola‐R‐CHP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!